Check your calendar and hop online; chances are, you’re probably near one of the DEA’s National Take Back Day’s nearly 5,500 disposal sites where local law enforcement will supervise a free, anonymous take back program between 10:00 a.m. – 2:00 p.m. this Saturday, April 27.
The Trans-Pacific Partnership (TPP) agreement has the potential to be an economic game-changer for the United States. Opening the growing markets of the Asia Pacific region would increase trade and exports, help continue our economic recovery and create new, high-paying jobs for American workers.
PhRMA explores the potential medicines in the biopharmaceutical pipeline on a regular basis through our Medicines in Development reports and other related efforts. Simply put, the pipeline is the foundation of PhRMA member companies.
A new report on the antibiotic pipeline is causing renewed concern given the emergence of antibiotic-resistant “superbugs” with high mortality rates.
Antibiotic-Resistance Poses Grave Danger
A passion to help others. Above all else, this is the prevailing quality inherent in the biopharmaceutical sector and in partners throughout the health care field. We help people live longer, better lives. We see it every day in the work we do and the people with whom we interact. This week, PhRMA is excited to be a part of two activities that epitomize this galvanizing mindset.
Every year, the PhRMA Foundation grants Awards in Excellence to past awardees who are dramatic, living proof that the Foundation program works and makes a difference. These awards are given to scientists who received a Foundation grant at the outset of their careers and went on to distinguish themselves through their scientific and/or academic achievements.
This morning's Research In Your Backyard (RIYB) event was a bright spot of hope amid an otherwise overcast day in Augusta, and PhRMA President and CEO (and longtime Maine resident) John Castellani spoke to his hometown crowd about the impact of clinical trials in Maine. With mor
Today there was legislation introduced by several members of Congress that would impose mandatory government price controls in the form of rebates in Medicare Part D.
A strong finish to #PhRMA13 today drove home the message that for patients, there is no greater source of hope than the continued medical innovation that leads to new treatments and further, new hope.
The past few days have been an excellent reminder of the accomplishments of our organization during the past year under the leadership of Dr. John Lechleiter. We have made important progress in our ongoing mission to protect and expand medical innovation and provide patients with access to disease-altering new therapies.
It’s obvious at #PhRMA13 that providing patients with the treatments they need is at the forefront of everyone’s mind. To determine what treatments are needed, patient engagement is becoming increasingly important.
The third and final panel today at #PhRMA13 tried on a new definition of what we consider "disruptive", and why we should like it. A disruptive technology or innovation improves not just what is known, but changes the modus operandi in completely unforeseen ways.
I’m at the PhRMA 2013 Annual Meeting in San Diego, where a panel is discussing disruptive innovation and the new challenges and opportunities it opens for the biopharmaceutical industry.
It’s a great topic.
The morning panels of PhRMA's Annual Meeting provided a welcome blast of new thinking on how to create a positive geography for innovation, and further how that science gets done. As an added bonus, California Lieutenant Governor Gavin Newsom gave a super-charged address explaining how a state in grave economic ﬂux plans to keep their leadership in bioscience.
Disruptive innovations in health care are often the drivers of new technologies and new treatments that enhance and build upon old modalities. The birth of osteopathic medicine in the 1870s can be seen as a “disruptive innovation” in its revolutionary approach to medical treatment.
According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980.
The expectation this year: Americans will spend $2.9 trillion on health care. And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.
There is certainly no lack of talent in the biopharmaceutical industry. Every day, employees are working hard in a variety of roles to ensure that patients get the treatments they need. It isn’t just the research scientists in the lab, it’s sales executives and communications staff who go above and beyond to advance research, progress and hope in everything they do.
The second #PhRMA13 panel begins at 1:45 pm EDT and will address medical breakthroughs and what needs to change to speed personalized medicine to patients. In a guest post, John Crosby, Executive Director at the American Osteopathic Association, addresses what he believes is necessary to bring science from the lab to the patient.